| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:[1-(2,4-dichloro-3-{[7-chloro-5-(trifluoromethyl)-1Hindol-1-yl]methyl}benzoyl)piperidin-4-yl]acetic acid
CAS:2055496-11-0
Purity:98% Package:5mg Remarks:S89347
|
|
| | 4-Piperidineacetic acid, 1-[2,4-dichloro-3-[[7-chloro-5-(trifluoromethyl)-1H-indol-1-yl]methyl]benzoyl]- Basic information |
| Product Name: | 4-Piperidineacetic acid, 1-[2,4-dichloro-3-[[7-chloro-5-(trifluoromethyl)-1H-indol-1-yl]methyl]benzoyl]- | | Synonyms: | 4-Piperidineacetic acid, 1-[2,4-dichloro-3-[[7-chloro-5-(trifluoromethyl)-1H-indol-1-yl]methyl]benzoyl]-;Cedirogant;ABBV-157;Inhibitor,inverse,ROR,Cedirogant,ABBV157,RORγt,RAR-related orphan receptor,psoriasis,inhibit,agonist,ABBV 157;Cedirogant, 10 mM in DMSO;[1-(2,4-dichloro-3-{[7-chloro-5-(trifluoromethyl)-1Hindol-1-yl]methyl}benzoyl)piperidin-4-yl]acetic acid;2-(1-(2,4-Dichloro-3-((7-chloro-5-(trifluoromethyl)-1H-indol-1-yl)methyl)benzoyl)piperidin-4-yl)acetic acid | | CAS: | 2055496-11-0 | | MF: | C24H20Cl3F3N2O3 | | MW: | 547.78 | | EINECS: | | | Product Categories: | | | Mol File: | 2055496-11-0.mol | ![4-Piperidineacetic acid, 1-[2,4-dichloro-3-[[7-chloro-5-(trifluoromethyl)-1H-indol-1-yl]methyl]benzoyl]- Structure](CAS/20210305/GIF/2055496-11-0.gif) |
| | 4-Piperidineacetic acid, 1-[2,4-dichloro-3-[[7-chloro-5-(trifluoromethyl)-1H-indol-1-yl]methyl]benzoyl]- Chemical Properties |
| Boiling point | 714.4±60.0 °C(Predicted) | | density | 1.52±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 250 mg/mL (456.39 mM; Need ultrasonic) | | form | Solid | | pka | 4.66±0.10(Predicted) | | color | White to off-white |
| | 4-Piperidineacetic acid, 1-[2,4-dichloro-3-[[7-chloro-5-(trifluoromethyl)-1H-indol-1-yl]methyl]benzoyl]- Usage And Synthesis |
| Uses | Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research[1][2]. | | References | [1] Elena Campione, et al. Experimental Pharmacological Management of Psoriasis. J Exp Pharmacol. 2021 Jul 26;13:725-737. DOI:10.2147/JEP.S265632
[2] Christian Gege. Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases - where are we presently Expert Opin Drug Discov. 2021 Jul 7;1-19. DOI:10.1080/17460441.2021.1948833 |
| | 4-Piperidineacetic acid, 1-[2,4-dichloro-3-[[7-chloro-5-(trifluoromethyl)-1H-indol-1-yl]methyl]benzoyl]- Preparation Products And Raw materials |
|